Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Post by HighSkies2019on Apr 27, 2021 7:01am
311 Views
Post# 33072738

Re: Buyout

Re: Buyout I was thinking buyout ...because the change of name at the beginning...and from yesterday's findings makes it more ??? ...but thinking over all the nr ..Claritas indicated the plan was to work with strategic partners globally...awhile back I thru a link out re Russia gave a pass on a new animal drug for covid protection .. and certain alot of investors were think WTF...I was thinking outside the box because at the exact same time claritas released about testing on animals dogs etc....Covance who did our testing also does work in Russia and our patent for R107 covers Russia ....so I am now thinking maybe that claritas is gonna be like a monopoly of collected companies in countries and operate as such...Claritas owns all rights to R107 lisence but other companies has access in countries of patent coverage ... can test in their country according to their governed rules....give it their own individual name and goveren pass as Russia has done...and Pfizer now has access to R107 for Covid and Pah to test and rename according to that country governed regulations ...now they can take it to market sell and we get percentage residuals kickbacks ....now even though they used R107 and renamed...other countries covered by patent usage can still get access to R107 to support what disease they want to test for ...say R107 is generic and other countries can get access do testing and put their own decorations on and call their own....now this is my thoughts of my own opinion ....glta
<< Previous
Bullboard Posts
Next >>